LUNG CANCER

A new supplemental biologics license application has been accepted by the FDA for pembrolizumab as treatment of patients with 1B (≥4 centimeters), 2, or 3 non-small cell lung cancer after complete surgical resection.

In patients with previously untreated, locally advanced stage III non–small cell lung cancer, continued benefit from pembrolizumab with concurrent chemoradiation followed by additional pembrolizumab was observed after more than 2 years of follow-up.

At the 2022 ASCO Annual Meeting, results from the GEMSTONE-302 trial showed that adding sugemalimab to chemotherapy improved survival in patients with metastatic non–small cell lung cancer.

According to Conor E. Steuer, MD, patritumab deruxtecan showed promising clinical activity in heavily pretreated patients with advanced non–small cell lung cancer with or without identified variant genomic alterations.

Correlations between non–small cell lung cancer the metastasizes to the brain and enriched CDKN2A/B and EGFR alterations calls for further genomic exploration of this patient population.

Adjuvant pembrolizumab led to improved disease-free survival versus placebo in patients with fully resected non–small cell lung cancer, according to second interim results from the PEARLS/KEYNOTE-091 trial.

Three-year follow-up of the CheckMate 9LA trial shows continued survival benefit to nivolumab/ipilimumab plus 2 cycles of chemotherapy in patients with metastatic non–small cell lung cancer.

The 5-year analysis of the CheckMate 227 study shows long-term survival benefit for nivolumab plus ipilimumab versus chemotherapy in patients with metastatic non–small cell lung cancer.

The use of pembrolizumab plus ramucirumab to treat non–small cell lung cancer in immune checkpoint inhibitor resistant patients showed better overall survival versus standard of care regimens in the Lung-MAP nonmatched phase 2 substudy S1800A.

Karen L. Reckamp, MD, explains the need for more treatment options for patients with non–small cell lung cancer who have been previously treated with immune checkpoint inhibitors and develop resistance.

During a Targeted Oncology case-based roundtable event, Mark A. Socinski, MD, discussed the results of clinical trials supporting the use of targeted agents in patients with late-stage lung cancers.

During a live virtual event, Aaron E. Lisberg, MD, discussed the value of molecular testing in patients recently diagnosed with early-stage lung cancer.

During a live virtual event, Ravi Salgia, MD, PhD, discussed treatment considerations for a patient with non–small cell lung cancer with a brain metastasis.

GEMSTONE-301 showed sugemalimab to demonstrate a statistically significant and clinically meaningful improvement in progression-free survival in patients with unresectable stage 3 non-small cell lung cancer without disease progression after concurrent or sequential chemoradiotherapy.

Findings from a retrospective real world study conducted in patients with EGFR-mutated, stage IV non–small cell lung cancer from 4 Latin American countries showed a 66% frequency rate in molecular testing and a frequency of EGFR mutations of 22% overall.

Martin Dietrich, MD, PhD, discusses the study design and results of the CheckMate 9LA trial of ipilimumab and nivolumab for patients with non–small cell lung cancer.

During a live virtual event, Anne S. Tsao, MD, discussed the choice of targeted therapy for a patient with non–small cell lung cancer with an EGFR exon 20 insertion.

A collaboration between Merck and Athenex, Inc. has been announced to evaluate oraxol plus pembrolizumab in certain patients with non-small cell lung cancer.

Results of a phase 1 study of a fourth-generation EGFR tyrosine kinase inhibitor will be presented at the International Association for the Study of Lung Cancer 2022 World Conference.

The SKYSCRAPER-01 study missed its co-primary end point of progression-free survival in patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer.

The demonstration of clinical benefit of oleclumab or monalizumab added to durvalumab vs durvalumab alone in the COAST study support further evaluation of these combinations in the larger study.

Breakthrough therapy designation has been granted to repotrectinib by the FDA for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer.

The first participants have been enrolled in the CASCADE-LUNG study, a prospective, multicenter trial.

During a live virtual event, Ravi Salgia, MD, PhD, discussed the use of immune checkpoint inhibitor monotherapy for a patient with non–small cell lung cancer with very high PD-L1 expression with participants.

As a follow-up to the success observed in the phase 2 COAST study, investigators of the phase 3 PACIFIC-9 have begun administering durvalumab in combination with monalizumab or oleclumab to patients with unresectable, stage III non–small cell lung cancer.

Nino Balanchivadze, MD, FACP, discusses the rationale for evaluating toxicity based on race in the KEYNOTE-189 study.

Treatment with avasopasem manganese reduced the incidence of radiation-induced, severe esophagitis in patients with lung cancer undergoing chemoradiotherapy, according to AESEOP trial findings.

Surface Oncology announced the initiation of new trials of the investigational agent SRF388 in patients with hepatocellular carcinoma and non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Jonathan Wesley Riess, MD, MS, discussed the case of a 72-year-old patient with non–small cell lung cancer with high PD-L1 expression.

Xiuning Le, MD, PhD, discusses counseling patients on the use of amivantamab-vmjw and mobocertinib and the sequencing of these drugs for patients with non–small cell lung cancer and an EGFR exon 20 insertion.